Single-Dose Combination Immunotherapy Augments Responses to Checkpoint Blockades for the Treatment of Cancer
Invention type: Technology
/
Case number: #21150H
The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
Researchers
Chensu Wang
/ Darrell Irvine
/ Karl Wittrup
Departments: Department of Biological Engineering, Department of Chemical Engineering
Technology Areas: Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living
-
combination immunotherapy dosing regimen for immune checkpoint blockade
United States of America | Granted | 11,235,032 -
single-dose combination immunotherapy augments responses to checkpoint blockades for the treatment of cancer
European Patent Convention | Published application -
combination immunotherapy dosing regimen for immune checkpoint blockade
United States of America | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.